|
|
||||||||
Department of Biochemistry and Molecular Biology, University of Minnesota, Duluth,Minnesota55812
| Abstract |
|---|
|
|
|---|
Key Words: rat dopamine-ß-monooxygenase tyrosine monooxygenase copper-deficient
| Introduction |
|---|
|
|
|---|
Dopamine-ß-monooxygenase (DBM) is a cuproenzyme that catalyzes the final step in the biosynthesis of norepinephrine (NE) by hydroxylating dopamine (DA) in an ascorbate- and oxygen-dependent reaction (3). DBM is located in adrenal medulla, sympathetic neurons, and noradrenergic and adrenergic neurons of the brain. DBM is essential for embryonic development of the mouse as demonstrated in recent studies in which the DBM gene was ablated (4). In humans the lack of DBM results in severe hypotension (5). It has not been clearly established if attenuation of DBM activity that occurs when Cu is limiting results in abnormal physiology. In fact the Cu story regarding DBM and catecholamines is quite puzzling.
Radioisotopic studies in rats indicated that dietary Cu deficiency decreased the conversion of cardiac DA to NE (6). Indeed, the steady-state NE concentration is lower in hearts from Cu deficient rats compared to controls (7).
Later it was shown that DA is elevated in hearts of Cu deficient rats supporting the hypothesis that DBM is altered by Cu deficiency in sympathetic nerves (8).
In the central nervous system the original Cu-DBM research is due in large part to the seminal work of Hunt and Johnson who studied mottled mice (9). Mutations at the mottled locus in mice are homologous with mutations in humans with Menkes disease. Brains of mutant mice converted less [3H]tyrosine to NE and more [3H]tyrosine to DA than control litter mates. Hunt and Johnson concluded that the former observation was due to decreased DBM and the latter to enhanced tyrosine monooxygenase (TM) activity, which they directly confirmed. They also reported lower steady-state NE levels in brain of the mutant mice compared to litter mates (9). Two years later Hunt reported that Cu was lower in brains of the mutant mice and the Cu-DBM connection in brain was formulated (10). Independently, it was reported that compared to controls brain NE was lower in Cu deficient rats (11). Lower NE was also observed in Cu-deficient lambs (12). Analyses in Cu-deficient rat and mouse brains detected lower NE concentrations in all regions except hypothalamus (1315). Cu-deficient rodents exhibit elevated DA in brain regions enriched in noradrenergic neurons (14, 15). Collectively, these data provide strong support for limiting DBM activity in brain following Cu deficiency.
However, direct DBM enzyme assay of whole brain homogenates demonstrated higher activity in mottled mice (10, 16) and higher activity following dietary Cu deficiency in mice (16) and rats (15). Regional analyses of six rat brain areas confirmed and extended these observations that DBM activity, measured in vitro, was higher in brains of Cu-deficient rats (17). Thus, in brain a paradox exists. On the basis of metabolite levels, DBM activity is lower, but on the basis of direct assay, DBM activity is higher following Cu deficiency.
DBM and catecholamine levels have also been studied in adrenal gland following Cu deficiency with mixed outcomes. Hesketh reported lower NE levels in adrenals of Cu-deficient rats and cattle (18, 19). Elevated DBM activity was measured in rat adrenal homogenates following postnatal Cu deficiency (1820). In young male rats, following perinatal Cu deficiency, adrenal DBM activity was also elevated (15). However, adrenal NE was not lowered by Cu deficiency in similar rats (20). Following postnatal Cu deficiency in rats, adrenal NE is sometimes unchanged and sometimes lower, whereas adrenal DA consistently is higher (8, 20). In Cu-deficient mottled blotchy mutant mice, total catecholamine content was unchanged but a 100% higher DBM activity was reported (21). Following dietary Cu deficiency, adrenal NE content was reported lower and DA higher in Cu-deficient mice (8). These facts suggest phenomena in adrenal gland similar to braina paradox between metabolite and enzyme assay data.
Assay of DBM requires addition of an agent, usually Cu2+ or N-ethylmaleimide (NEM) to inactivate an endogenous inhibitor. Regardless of the addition of NEM or Cu2+, mouse brain DBM activity was higher in brindled mice or Cu-deficient mice than in controls (16). Mixing experiments also failed to detect any differences in the levels of activators or inhibitors between Cu-deficient and Cu-adequate rats (20). Protein levels of DBM have not been measured following Cu deficiency.
Recent experiments on brain and adrenal gland in two models of dietary Cu deficiency, a postnatal model studying the impact of postweaning Cu deficiency and a perinatal model studying the impact of gestationallactational Cu deficiency, detected a robust increase in the steady-state DBM mRNA levels in Cu-deficient rats (20). This suggests that the elevated DBM activity, reported previously, might be due to increased formation of DBM protein. However, transcript levels do not always reflect protein levels following Cu deficiency. For example, Chen et al. showed that the mRNA for metallothionein (MT) in liver of Cu-deficient rats was elevated 75-fold compared to Cu-adequate rats, but MT protein was unchanged (22). Following Cu deficiency another group reported a 1.5-fold increase in olfactory bulb mRNA for neuropeptide Y but were unable to detect changes in immunoreactive peptide (23). The purpose of the present experiments was to test the hypothesis that increased DBM protein levels accompany dietary Cu deficiency. A second purpose was to assess the levels of TM following Cu deficiency since DBM and TM are often coordinately regulated.
| Methods and Materials |
|---|
|
|
|---|
Pregnant dams were placed on the Cu-deficient treatment 7 days after they were identified as sperm-positive. Two days following parturition litter size was adjusted to eight pups. Offspring were weaned when 21 days old, placed in stainless steel cages, and maintained on the same treatment as their respective dams for an additional 9 days. A total of 12 litters (6 Cu-adequate and 6 Cu-deficient) were sampled. This paradigm is similar to that used previously to study neurochemical changes in young rats (15). Males and females were killed on consecutive days.
Sample Collection.
Offspring of dams were sampled at age 30 days. Blood samples were drawn into heparinized microhematocrit tubes from trunk blood following decapitation after light ether anesthesia. A small aliquot was also removed for hemoglobin analysis. Additional blood was collected in plastic tubes and allowed to clot. Plasma and serum were obtained by centrifugation. Livers were removed, rinsed with deionized water, and weighed and a portion was processed for metal analysis. Adrenal glands were removed, weighed to the nearest mg, and quick-frozen in liquid nitrogen. Brains were removed, and the cerebellum and hypothalamus were weighed and quick-frozen. Cerebella were analyzed for Cu and the hypothalamus for DBM, TM, and Cu,Zn-superoxide dismutase (SOD).
Chemical Analyses.
Portions of liver, cerebella, and 1-g samples of diets were wet-digested with 4 ml of concentrated HNO3 (AR select grade, Mallinckrodt, St. Louis, MO), and the residue was brought to 4.0 ml with 0.1 mol/l HNO3. Samples were then analyzed for Cu and Fe by flame atomic absorption spectroscopy (Model 2380, Perkin-Elmer, Norwalk, CT). Total protein content of adrenal and hypothalamus extracts was determined by analysis using a modified Lowry method with bovine albumin as a reference (24).
Enzyme Assays.
DBM (EC 1.14.17.1) activity of adrenal gland and hypothalamus was determined spectrophotometrically by measuring conversion of tyramine to octopamine as described previously (16). The endogenous inhibitor of DBM activity was inactivated by 25 mmol/l N-ethylmaleimide (NEM) rather than Cu. Pairs of adrenal glands or brain tissues were homogenized for 30 sec in 9 vol of 0.05 mol/l potassium phosphate (pH 7.0) with a Tissumizer and microprobe (SDT-080EN, Tekmar Co., Cincinnati, OH). Homogenates were diluted in 0.005 mol/l potassium phosphate (pH 7.0) containing 0.2% Triton X-100 and centrifuged at 6,500g for 10 min. The phosphateTriton buffer was stored in an acid-washed bottle containing 1 g of Chelex 100 (Bio-Rad Laboratories Inc., Hercules, CA) suspended within dialysis tubing. DBM activities were expressed per milligram of total protein. Activity of SOD (EC 1.15.1.1) was measured spectrophotometrically by monitoring inhibition of pyrogallol autoxidation at 320 nm as described previously (25).
Northern Blot Analysis.
Total adrenal RNA was isolated from quick-frozen samples using a modified guanidine thiocyanate/phenol/chloroform procedure described in detail elsewhere (20). Total RNA was size fractionated on 1.5% agarose gels containing 2 mol/l formaldehyde and 0.02 mol/l sodium phosphate (pH 7.0) and transferred to Nytran Plus® membranes (Schleicher & Schuell, Keene, NH) by upward capillary transfer. Positions of 28S and 18S ribosomal RNA were marked after transfer. The membranes were then hybridized overnight with a purified 32P random-primed 2.2-kb probe for rat DBM (1.7 ng/ml) (26). Membranes were washed several times and exposed to film (20). After autoradiography, membranes were stripped and rehybridized with a 32P-labeled 1.2-kb probe for mouse 18S ribosomal RNA (Ambion, Austin, TX) to verify equal loading and transfer of RNA. Images of autoradiograms were captured using Gel Doc 1000 (Bio-Rad) interfaced with a Macintosh PPC computer, and band density profiles were integrated using the manufacture's software, Molecular Analyst (Bio-Rad).
Western Blot Analysis.
Protein extracts from adrenal gland and hypothalamus were prepared in 0.05 mol/l potassium phosphate (pH 7.0) containing 0.2% Triton X-100 and mammalian protease inhibitor cocktail (Sigma P8340). Homogenates were centrifuged 1,000g for 10 min at 4°C to remove debris. Protein concentration was determined and samples diluted 1:4 with Laemmli sample buffer (0.0625 mol/l Tris (pH 6.8), 10% glycerol, 2% SDS, 5% mercaptoethanol, 0.00125% bromophenol blue) and heated (boiling water bath 5 min) prior to loading. Proteins were size fractionated on 10% SDS-PAGE gels and electroblot transferred to 0.2 µM nitrocellulose membranes (Protran, Schleicher & Schuell).
Membranes were stained with Ponceau S (Sigma Chemical Co.) to ensure equal loading and to locate molecular weight markers. Immunoblotting was carried out at room temperature. Membranes were incubated with blocking solution (0.05 mol/l Tris (pH 8.0), 2 mmol/l CaCl2, 0.08 mol/l NaCl, 5% non-fat dry milk, 0.2% Tween-20, and 0.02% sodium azide) with shaking for 45 min. Membranes were then incubated overnight or for 3 hr in seal-a-meal bags with primary antibody diluted 1:600 for DBM and 1:1,500 for TM, in TBST (0.05 mol/l Tris (pH 8.0), 0.9% NaCl, 0.1% Tween-20) and 1% blocking solution. Antibodies for DBM, rabbit anti-human DBM (AB 1538), and for TM, rabbit anti-rat TM (AB 152), were purchased commercially (Chemicon International Inc., Temecula, CA). For hypothalamus membranes, DBM was also probed using rabbit anti-rat DBM diluted 1:1,500 with antiserum against recombinant rat DBM (27). Following primary antibody incubation, membranes were washed with TBST (3 times for 5 min each), then were incubated for 1 hr with secondary antibody, donkey anti-rabbit IgG conjugated to horseradish peroxidase (Amersham NA 934), diluted 1:5,000 in TBST. Membranes were then washed with TBST (3 times for 5 min each) and TBS (5 min). Detection measured chemiluminescence (ECLTM, Amersham, Piscataway, NJ) exposing membranes to film (Kodak X-OMAT LS). Densitometry was performed using the manufacture's software (Bio-Rad). Size of the immunoreactive bands was estimated from regression analysis using standard peptides (Bio-Rad) log[molecular weight] versus protein distance migrated.
Following primary target protein detection, membranes were directly reprobed for actin to ensure even sample loading and protein transfer (28). Membranes, previously probed for DBM and TM, were wrapped in plastic overnight at room temperature or up to 6 months at -20°C. They were washed with TBST for 10 min. and incubated with primary antibody, mouse anti-chicken actin (MAB1501R, Chemicon International Inc.), as described above at a 1:10,000 dilution. After being washed, secondary antibody incubation and detection was performed as above with peroxidase conjugated goat anti-mouse IgG (Pierce 31434ZZ, Rockford, IL) at a 1:10,000 dilution.
Statistical Analyses.
The effect of maternal Cu intake on offspring characteristics were analyzed by factorial ANOVA and significant interaction terms by Fisher's PLSD test,
= 0.05 (Statview 4.5, Abacus Concepts, Inc., Berkeley, CA). Student's t-test was used when comparing data in which diet was the only variable,
= 0.05.
| Results |
|---|
|
|
|---|
|
Adrenal glands from half the female offspring were assayed for DBM enzyme activity (Fig. 1
). Compared to +CuF the DBM activity in the -CuF samples was 42% higher (P < 0.05). Protein concentration in the adrenal supernates was not altered by Cu deficiency. DBM activity was also measured on thawed homogenates of female offspring (Fig. 1
). Activity is much lower in hypothalamus tissue compared to adrenal gland but activity of -CuF samples was higher than +CuF samples (P < 0.001).
|
|
|
|
|
Our earlier diet work on perinatal rats studied mRNA changes in the medulla/pons, thus, we conducted new studies using Western immunoblots from 24-day-old +CuF and -CuF rats (n = 6 each). Compared to +CuF rats the cerebral cortex Cu values were decreased 83%, 0.361 ± 0.025 µg/g compared to 2.12 ± 0.036 µg/g, P < 0.01. DBM activity was 41% higher in -CuF than +CuF samples, 4.32 ± 0.23 nmol/hr/mg protein compared to 3.06 ± 0.23. However, we failed to detect a difference in DBM density of the 76-kDa band (30 µg was loaded), -Cu/+Cu = 1.05. We also ran a separate gel and membrane for TM. There was no consistent or statistical difference between +CuF and -CuF medulla/pons samples in the twelve lanes for the 61-kDa band (10 µg protein was loaded). The signals were variable with an average -Cu/+Cu = 1.20.
| Discussion |
|---|
|
|
|---|
The 40% enhancement in DBM protein in -Cu rats implied by density of the lanes was similar to the enhancement in enzyme activity, suggesting, but not proving, that the higher in vitro enzyme activity of DBM in Cu deficiency is due to the presence of the higher DBM protein concentration. Previous mixing experiments failed to detect any abnormal amounts of activators in homogenates from Cu-deficient rats (20). Further support for higher DBM protein is evident by the enhanced density (-Cu/+Cu = 2.0) of adrenal DBM peptides in Western blots of 49-day-old male Holtzman rats subjected to 30 days of postnatal Cu deficiency (data not shown). These Cu-deficient rats also have higher (-Cu/+Cu = 2.4) DBM enzyme activity and higher (-Cu/+Cu = 2.8) DBM mRNA concentrations (20). Collectively these data strongly suggest that adrenal tissue from Cu-deficient rats contains higher concentrations of DBM protein than Cu-adequate rats. The enhancement in DBM mRNA in both models of Cu deficiency seem to exceed the enhancement in DBM protein levels; however, they were determined on different animals and in opposite genders in the case of the current studies. Adrenal extracts from 30-day-old -CuF rats contained higher TM levels detected by Western immunoblot analysis compared to +CuF extracts. The coding sequence of rat TM mRNA predicts a peptide of 56 kDa (31). However, we detected a single band of apparent size equal to 61 kDa. This is consistent with prior work by others using a different antibody to rat TM (32).
The chemical signal that results in enhanced adrenal DBM and TM has not been identified. These proteins often change in concert because they share common promoter elements and respond to cAMP, glucocorticoids, and other chemokines (3335). A logical hypothesis would be that Cu deficiency leads to elevated TM and DBM synthesis due to decreased levels of norepinephrine (NE). Epinephrine levels in adrenal gland of Cu-deficient rodents are not altered (8, 20). Reserprine, a drug that depletes adrenal catecholamines, leads to induction of adrenal DBM and TH (26, 36).
However, the data in Cu deficiency do not always support this hypothesis. Rats, similar to those studied in the current experiments, were shown to have no decrease in adrenal NE following Cu deficiency even though DBM mRNA was elevated markedly (20). Sabban et al. communicated similar findings (37). Moreover, mottled brindled mice, characterized by Cu deficiency because of a mutation in the ATP7A Cu efflux transporter gene, were found to have no alterations in adrenal DBM or TM activity despite a 42% reduction in adrenal catecholamines (21). The only consistent alteration in a catecholamine following Cu deficiency associated with elevated DBM is the robust increase in dopamine (DA). Thus, further research will be necessary to elucidate the signal that enhances DBM synthesis in Cu deficiency.
Reserpine treatment of rats is also associated with elevated TM and DBM in brain stem (38). Brain stems of -Cu rats contain lower NE and higher DA than +Cu offspring (15). Previously, higher DBM enzyme activity was reported in several rat brain regions, including hypothalamus and medulla/pons, for both -CuF and -CuM offspring (17). The -CuF rats in the current studies also had higher brain DBM activities than Cu-adequate controls. Thus, it was unexpected that we were unable to detect differences in DBM protein levels by Western immunoblot in hypothalamus or medulla/pons extracts from -CuF compared to +CuF rats. The DBM immunoblot procedure does not have the same sensitivity as the DBM assay, and the changes in brain DBM are less than in adrenal gland. In -CuF rats the medulla/pons DBM mRNA elevation was approximately 50% (20). However, it may also be possible that the apparent higher DBM activity is due to something besides higher DBM protein levels.
It should be pointed out, however, that despite the presence of higher brain DBM enzyme activity, mRNA, and, perhaps, protein, the functional activity of the enzyme appears to be lower rather than higher. The concentration of NE is lower and that of DA, the precursor, is higher in those Cu-deficient rodent brain regions innervated by noradrenergic neurons (14, 15). The lower NE, we hypothesize, is because the intracellular Cu is not sufficient to bind to apo-DBM to act as a cofactor. DBM undergoes facile Cu exchange in contrast to other cuproenzymes (39). The higher DA could be a combination of slower conversion by limiting DBM and enhanced synthesis by higher TM activity. These alternative hypotheses require further testing.
The current Cu-deficient studies in rats found no change in hypothalamus or medulla/pons TM protein levels by immunoblot analysis, whereas previous work in rats detected lower forebrain TM activity (40). In Cu-deficient brindled mice, higher TM activity in brain was detected in experiments following labeled tyrosine (9). Additional research on copper and catecholamine metabolism are needed to clarify these somewhat divergent observations on TM. It does seem that both brain stem TM and DBM change in response to stress (27). Restriction of Cu can be thought of as a physiological stress.
| Acknowledgments |
|---|
| Footnotes |
|---|
1 To whom correspondence should be addressed at Department of Biochemistry and Molecular Biology, University of MinnesotaDuluth, 10 University Drive, Duluth, MN 55812. E-mail: jprohask{at}d.umn.edu ![]()
| References |
|---|
|
|
|---|
-amidating monooxygenase and other cuproenzyme activities following perinatal copper deficiency. Proc Soc Exp Biol Med 210:107116, 1995.[Abstract]
This article has been cited by other articles:
![]() |
A. A. Gybina and J. R. Prohaska Fructose-2,6-Bisphosphate Is Lower in Copper Deficient Rat Cerebellum Despite Higher Content of Phosphorylated AMP-Activated Protein Kinase Experimental Biology and Medicine, October 1, 2008; 233(10): 1262 - 1270. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. W. Pyatskowit and J. R. Prohaska Iron Injection Restores Brain Iron and Hemoglobin Deficits in Perinatal Copper-Deficient Rats J. Nutr., October 1, 2008; 138(10): 1880 - 1886. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K Georgieff Nutrition and the developing brain: nutrient priorities and measurement Am. J. Clinical Nutrition, February 1, 2007; 85(2): 614S - 620S. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-M. Kuo, A. A. Gybina, J. W. Pyatskowit, J. Gitschier, and J. R. Prohaska Copper Transport Protein (Ctr1) Levels in Mice Are Tissue Specific and Dependent on Copper Status J. Nutr., January 1, 2006; 136(1): 21 - 26. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. C. West and J. R. Prohaska Cu,Zn-Superoxide Dismutase Is Lower and Copper Chaperone CCS Is Higher in Erythrocytes of Copper-Deficient Rats and Mice Experimental Biology and Medicine, September 1, 2004; 229(8): 756 - 764. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Gybina and J. R. Prohaska Increased Rat Brain Cytochrome C Correlates with Degree of Perinatal Copper Deficiency Rather than Apoptosis J. Nutr., November 1, 2003; 133(11): 3361 - 3368. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Prohaska, J. Geissler, B. Brokate, and M. Broderius Copper, Zinc-Superoxide Dismutase Protein but not mRNA Is Lower in Copper-Deficient Mice and Mice Lacking the Copper Chaperone for Superoxide Dismutase Experimental Biology and Medicine, September 1, 2003; 228(8): 959 - 966. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |